Pharma & Biotech Global Week in Review 17 Feb 2010 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Lipitor (Atorvastatin) – Philippines: UniLab can still sell generic version of Pfizer’s Lipitor after a Makati court denies latter’s petition for preliminary injunction (GenericsWeb)

Famvir (Famciclovir) – US: Teva and Novartis settle patent litigation regarding Famciclovir (IP Factor) (SmartBrief)

 
General

Gates Foundation seeks to make this ‘the decade of vaccines’ (Patent Docs)

WTO members to consider review of TRIPS public health amendment (IP Watch)

Repurposing, repatenting… and SPC’s – Lawtext Bio-Science Law Review article (SPC Blog)

Agrochemicals, generics and competition – Farmers’ Weekly Interactive article (SPC Blog)

Australia / US: Hands off my genes! (IP Whiteboard)

EU: European Commission probes for evidence of foul play among pharmaceutical companies (IP Whiteboard)

EU / UK: Of conflict and cooperation: when national courts and the EPO differ: Eli Lilly and Company v Human Genome Sciences (PatLit)

India: Drug makers decry Indian patent law (GenericsWeb)

India: India-EU gets flak in India (GenericsWeb)

India: Delhi High Court: Rejection of application based on pre-grant representation may be appealed to IPAB: UCB Farchim SA v Cipla & Ors (SiNApSE)

Mexico: Supreme Court decision states linkage system between the Mexican Patent Office (IMPI) and Mexican Health Authority (COFEPRIS) should not be delimited to compound patents but should also include product patents covering pharmaceutical formulations (Moeller IP)

Mexico: Genetically modified organism, green light to consume but not to plant? (IP Tango)

Poland: differences in pharmaceutical trade marks (Class 46)

South Africa: Court of the Commissioner of Patents: Interdict pends ‘pending’ decision: Sanofi v Cipla Medpro (Afro-IP)

UK: Official UK patent law reports focus on SPCs (The SPC Blog)

US: Pruning priority to prolong the patent – US patent covering ‘methods and compositions for stimulating the immune system’ (12:01 Tuesday)

US: Bio sends letter on SACGHS Report to HHS Secretary Sebelius (Patent Docs)

US: Debating gene patents – Round Four – debate held on WBUR’s ‘On Point’ (Patent Docs)

US: Advisory Group: ‘Near perfect storm’ coming on gene patents in the US (IP Watch)

US: FTC disapproves of ‘pay-for-delay’ drug deals (Patent Docs)

US: Alzheimer’s Institute of America files patent infringement suit against Elan and others’ over alleged use of its Alzheimer disease related technology (Patent Docs)

US: Genetic Technologies files patent infringement suit against Beckman Coulter over their sale or offering of genotyping and genomic services(Patent Docs)

 
Products

Colchicine – US: Federal Court recognizes lack of private enforcement of FDC Act, but permits private lawsuit seeking to block unapproved drugs to proceed anyway FDA Law Blog)

Coversyl (Perindopril) – UK: Late stage amendments – a success for Servier: Les Laboratoires Servier & Anor v Apotex Inc & Ors (PatLit)

Embeda (Morphine, Naltrexone) – US: Patent infringement complaint based on defendant’s manufacture and sale of generic Embeda product: Purdue Pharma L.P. v. King Pharmaceuticals Inc. et al (Patent Docs)

Famvir (Famciclovir) – US: Teva and Novartis settle patent litigation regarding Famciclovir (IP Factor) (SmartBrief)

Gardasil, Silgard – Portugal: More on Gardasil and Silgard from Portugal (SPC Blog)

Lipitor (Atorvastatin) – Philippines: UniLab can still sell generic version of Pfizer’s Lipitor after a Makati court denies latter’s petition for preliminary injunction (GenericsWeb)

Mucinex (Guaifenesin) – US: W D Michigan rules Perrigo does not infringe Adams Respiratory Therapeutics Mucinex patent (GenericsWeb)

Nexavar (Sorafenib) – India: Bayer may move Supreme Court on Sorafenib patents even as Cipla prepares to launch generic Nexavar in India (GenericsWeb)

Nexium (Esomeprazole) – US: Request for declaratory judgment of noninfringement in connection with ANDA to manufacture generic version of Astra Zeneca’s Nexium: Lupin Ltd et al. v. Merck, Sharp & Dohme Corp. (Patent Docs)

Razadyne (Galantamine) / Strattera (Atomoxetine) – US: Walking the enablement/non-obviousness tightrope: Janssen Pharmaceutica N.V. v. Teva Pharms. USA, Inc; Eli Lilly & Co. v. Actavis Elizabeth LLC, et al. (Orange Book Blog)

Taron A Prenatal – US: US: Patent infringement complaint filed in W D Texas based on defendant’s manufacture and sale of Taron A Prenatal supplement: Mission Pharmacal Co. v. Trigen Laboratories, Inc (Patent Docs)

Tramadol – France: Preliminary injunctions in case of an ‘imminent infringement’: Mylan v Medochemie (EPLAW)

 

%d bloggers like this: